DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing
13 Pages, 1 Figure, 4 tables. The authors’ affiliations are listed in the Supplementary Appendix, available at NEJM.org. Supplementary Material, available at http://dx.doi.org/10.1056/NEJMoa1800474, BACKGROUND:
The World Health Organization recommends drug-susceptibility testing of Mycobacterium tuberculosis complex for all patients with tuberculosis to guide treatment decisions and improve outcomes. Whether DNA sequencing can be used to accurately predict profiles of susceptibility to first-line antituberculosis drugs has not been clear.
METHODS:
We obtained whole-genome sequences and associated phenotypes of resistance or susceptibility to the first-line antituberculosis drugs isoniazid, rifampin, ethambutol, and pyrazinamide for isolates from 16 countries across six continents. For each isolate, mutations associated with drug resistance and drug susceptibility were identified across nine genes, and individual phenotypes were predicted unless mutations of unknown association were also present. To identify how whole-genome sequencing might direct first-line drug therapy, complete susceptibility profiles were predicted. These profiles were predicted to be susceptible to all four drugs (i.e., pansusceptible) if they were predicted to be susceptible to isoniazid and to the other drugs or if they contained mutations of unknown association in genes that affect susceptibility to the other drugs. We simulated the way in which the negative predictive value changed with the prevalence of drug resistance.
RESULTS:
A total of 10,209 isolates were analyzed. The largest proportion of phenotypes was predicted for rifampin (9660 [95.4%] of 10,130) and the smallest was predicted for ethambutol (8794 [89.8%] of 9794). Resistance to isoniazid, rifampin, ethambutol, and pyrazinamide was correctly predicted with 97.1%, 97.5%, 94.6%, and 91.3% sensitivity, respectively, and susceptibility to these drugs was correctly predicted with 99.0%, 98.8%, 93.6%, and 96.8% specificity. Of the 7516 isolates with complete phenotypic drug-susceptibility profiles, 5865 (78.0%) had complete genotypic predictions, among which 5250 profiles (89.5%) were correctly predicted. Among the 4037 phenotypic profiles that were predicted to be pansusceptible, 3952 (97.9%) were correctly predicted.
CONCLUSIONS:
Genotypic predictions of the susceptibility of M. tuberculosis to first-line drugs were found to be correlated with phenotypic susceptibility to these drugs. (Funded by the Bill and Melinda Gates Foundation and others.)., Supported by grants from the Bill and Melinda Gates Foundation
(OPP1133541, to CRyPTIC, plus separate support to Dr.
Rodwell), a Wellcome Trust/Newton Fund–MRC Collaborative
Award (200205/Z/15/Z, to CRyPTIC), the National Institute for
Health Research (NIHR) Oxford Biomedical Research Centre
(BRC) and NIHR Health Protection Research Unit in Healthcare
Associated Infections and Antimicrobial Resistance at University
of Oxford in partnership with Public Health England, the
NIHR Biomedical Research Centre at Barts, the NIHR Biomedical
Research Centre at Imperial, the NIHR and NHS England (to
the 100,000 Genomes Project, which is managed by Genomics
England, a wholly owned company of the U.K. Department of
Health), the Wellcome Trust, the Medical Research Council,
Public Health England, a grant from the National Science and
Technology Key Program of China (2014ZX10003002), a grant
from the National Basic Research program of China
(2014CB744403), a grant from the Strategic Priority Research
Program of the Chinese Academy of Sciences (XDB29020000), a
grant from the European Commission Seventh Framework Program
(FP7/2007-2013, to Borstel under grant agreement 278864
in the framework of the Patho-NGen-Trace project), the German
Center for Infection Research (to Borstel), Leibniz Science Campus
Evolutionary Medicine of the Lung (EvoLUNG), the Belgian
Ministry of Social Affairs (to the Belgian Reference Center for
Tuberculosis and Mycobacteria from Bacterial Diseases Service
through a fund within the Health Insurance System), the French
governmental program “Investing for the Future” (to Genoscreen),
a grant from the European Commission Seventh Framework
Program (FP7/2007-2013, to Genoscreen under grant
agreement 278864 in the framework of the Patho-NGen-Trace
project), grants from the Drug Resistant Tuberculosis Fund
(R015833003, to Dr. Chaiprasert), the Faculty of Medicine, Siriraj
Hospital, Mahidol University (to Dr. Chaiprasert), a grant
from the Ministry of Economy and Competitiveness (MINECO),
Spain (SAF2016-77346-R, to Dr. Comas), a grant from the European
Research Council (638553-TB-ACCELERATE, to Dr. Comas),
a grant from the BC Centre for Disease Control Foundation
for Population and Public Health (to Dr. Gardy), a grant
from the British Colombia Lung Association (to Dr. Gardy),
grants from the Wellcome Trust and the Royal Society
(101237/Z/13/Z and 102541/A/13/Z, to Drs. Wilson and Iqbal [Sir
Henry Dale Fellows]), a grant from the National University of
Singapore Yong Loo Lin School of Medicine Aspiration Fund
(NUHSRO/2014/069/AF-New Idea/04, to Drs. Ong and Teo), a
European Commission Seventh Framework Program European
Genetic Network (EUROGEN) grant (201483, to Dr. Drobniewski),
and the National Institute of Allergy and Infectious Diseases,
National Institutes of Health (to Dr. Rodwell). Dr. T. Walker
is an NIHR Academic Clinical Lecturer, and Drs. Crook, Peto,
and Caulfield are NIHR Senior Investigators.
No potential conflict of interest relevant to this article was
reported.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
We thank Stéphanie Duthoy, Carina Hahn, Alamdar Hussain,
Yannick Laurent, Mathilde Mairey, Vanessa Mohr, and Mahmood
Qadir for technical assistance and George F. Gao, Director
of the Chinese Center for Disease Control and Prevention, for
directing the Chinese grant and sequencing program, Peer reviewed